ArticleDiagnostic pathology2026
Adenocarcinoma admixed with neuroendocrine carcinoma of the cervix: a clinicopathological diagnostic study and molecular features.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCervical adenocarcinoma admixed with neuroendocrine carcinoma (A-NEC) is a rare and aggressive tumor with limited molecular characterization and no standardized treatment. This study aims to delineate its clinicopathological and molecular features to improve diagnostic accuracy and identify potential therapeutic targets.
methodsFourteen rigorously diagnosed cervical A-NEC cases (2016–2024) were retrospectively analyzed according to the WHO 2020 criteria. Comprehensive evaluation included cytology, histomorphology, HPV genotyping, and immunohistochemical profiling of neuroendocrine markers, Ki-67, p53, PTEN, PI3K, and PD-L1.
resultsAll patients presented with abnormal bleeding or discharge. While cytology detected abnormalities in all evaluable cases (10/10), it did not identify neuroendocrine components. Histology revealed interdigitated HPV-associated adenocarcinoma and neuroendocrine carcinoma (predominantly small cell type). Molecular analysis showed component-specific heterogeneity: although TP53 and PD-L1 expression were concordant, the neuroendocrine component exhibited PTEN loss in all 8 evaluable cases (8/8) and PI3K overexpression in 5/8 cases-a pattern not observed in adenocarcinoma components. NEC demonstrated high proliferative activity (median Ki-67 80%). Survival events were concentrated within the first 24 months.
conclusionThis clinicopathological analysis of 14 cervical A‑NEC cases highlights the diagnostic limitations of cytology and the need for histopathological confirmation in surgical specimens. The neuroendocrine component exhibits distinct molecular features (PTEN loss, PI3K overexpression), indicating dysregulation of the PI3K‑AKT‑mTOR pathway as a potential research target. Most events occur within 24 months, underscoring the importance of early monitoring. These findings improve the understanding of this rare malignancy and support future multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.